You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧賽圖(02315.HK)與ADC Therapeutics(ADCT.US)簽署抗體藥物分子評估及授權協議
百奧賽圖(02315.HK)宣布,與ADC Therapeutics SA(ADCT.US)簽署具有選擇權的抗體藥物分子評估與授權協議,百奧賽圖將授權ADC Therapeutics針對公司具有自主知識產權的3個腫瘤靶點的抗體分子進行評估。 在完成評估後,ADC Therapeutics有權獲得其所選定的抗體分子授權,在全球範圍內用於ADC藥物開發和商業化;而百奧賽圖將保留這些抗體分子用於除ADC藥物以外的所有全球權益。 百奧賽圖將獲得首付款,針對每個許可分子將獲得選擇權執行費、不同階段開發和商業化里程碑付款,累計可達數千萬美元,以及個位數淨銷售額分成。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account